a) High Potential: Cord tissue is a rich source of Mesenchymal precursor cells capable of giving rise to fat, cartilage, bone, and skeletal muscle cells, and thus may potentially be used for regenerative stem cell therapy in several disorders. The number of mesenchymal cells found within the mononucleated cell population is higher than bone marrow.

b) Proliferative properties: Mesenchymal stem cells from the umbilical cord tissue are more proliferative; hence larger numbers can be obtained on expansion from small initial numbers.

c) Multiple Dosages: Laboratory techniques are now well developed, that allow obtaining unlimited numbers of purified mesenchymal precursor cells, and thereby make available these valuable stem cells for therapeutic use more than once.

d) Approaching regulatory approval: Mesenchymal stem cells are now being used in over 100 clinical trials, including two phase III clinical trials, both of which have been fast-tracked by the FDA for commercialization.

e) Ease in administration: Unlike other cell therapies these cells are administered through a standard IV line like many of the other drugs that are given to patients.

f) Safety: These stem cells are well tolerated, with no patient deaths, no toxicity or any adverse side effects reported, thus providing for large-scale clinical use.

g) Pain: Bone marrow harvesting is an invasive and painful procedure while cord tissue extraction is quick, painless and harmless to both mother and baby.